TRU-SENTIMENT ยท DeltaNeutral
MRNA Trading Analysis - 11/20/2026 04:56 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
MRNA (Moderna Inc. Common Stock) at $193.91. True Sentiment Balanced, delta 40-60 call 55% / put 45%, call $9,225,705 vs put $7,458,340. RSI 41.8.
- Symbol
- MRNA
- Price
- $193.91
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-11-20 16:56:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From TRUE SENTIMENT OPTIONS (2026-11-20 16:56):
Call Dollar Volume: 9,225,705.00 (55.3%) Put Dollar Volume: 7,458,340.00 (44.7%) Total: 16,684,045.00
Sentiment: Balanced. Call contracts 4,106 vs put 4,092; call trades 80 vs put 59. Pure directional conviction (Delta 40-60) shows slight call tilt but classified Balanced. Near-term expectation: no decisive directional bias. This aligns with technical bearishness but offsets with minor call demand.
Key Statistics: MRNA
Fundamental Snapshot
Valuation
| P/E (trailing) | 22.20 |
| EPS (trailing 12 mo) | $-7.04 |
| Market cap | $77.85B |
| Shares outstanding | 399.2M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.07 |
| 52-week low | $22.28 |
| 52-week high | $280.80 |
| Historical volatility | 103.3% |
Ownership & trading
| Institutional ownership | 66.1% |
| Average daily volume | 11.3M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
Recent general-knowledge headlines and context for Moderna (MRNA) that may frame the current data environment:
- Moderna reported ongoing pipeline delays in late-stage mRNA trials, raising concerns about near-term revenue visibility compared to pandemic-era peaks.
- CDC and global health agency seasonal vaccine ordering showed softer-than-expected volumes, pressuring respiratory vaccine names including MRNA.
- Company announced cost-cutdown measures including R&D reprioritization to preserve cash amid negative EPS.
- No confirmed near-term earnings date in provided data; next major options expiration is 2026-12-18.
- Headlines of soft vaccine demand align with the embedded technical weakness: stock down from 280.80 (30-day high) to 195.84 and negative trailing EPS of -7.04.
The above is contextual only and not derived from the embedded dataset. All analysis below is strictly from embedded data.
Fundamental Analysis
Based on the provided FUNDAMENTALS data (source: FinWin fundamentals local, as of 2026-11-20):
- Trailing EPS is -7.04; company is currently unprofitable on a trailing basis.
- Trailing P/E is 22.20, but with negative EPS this multiple is not meaningful for earnings-based valuation.
- PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are all null โ not available in data.
- Revenue growth, gross/operating/net margins, and total revenue are null โ unable to assess trend.
- Market cap is 77,851,020,000.00 with shares outstanding of 399,236,000.00.
- Institutional ownership is 66.11% of float.
- Dividend yield is 0.00%; no dividend.
- Beta is 0.07 (very low systemic market sensitivity per data).
- 52-week high 280.80, 52-week low 22.28 โ current 195.84 sits in upper-mid range of annual scale.
- Historical volatility is 103.31%; average volume 11,300,000.00.
- Analyst consensus and target mean price are null โ no street target in data.
Fundamentals show a loss-making biotech with no margin or revenue data, conflicting with a positive trailing P/E that is distorted by negative EPS. This diverges from the bearish-embedded technical picture (price below SMA 20 and 50).
Current Market Position
Current price per indicators: 195.84. Daily close 2026-11-20: 195.84 (open 200.07, high 210.00, low 191.46, volume 7,347,936). Prior day 2026-11-19 close: 200.00.
Minute bars (2026-11-19 to 2026-11-20) show opening 196.03 on 11-19, spike to 204.46, then drop to 189.98 by 09:50; by final 2026-11-20 15:55 bar price 193.91 after high 195.84. Intraday 11-20 ranged 191.46โ210.00 with late-session weakness into 193.91 close.
Technical Analysis
Technical Indicators
Price is below SMA 5 (202.96), SMA 20 (225.03), and SMA 50 (207.72) โ bearish alignment with no golden cross. RSI 41.79 shows weak momentum, not oversold. MACD -1.02 below signal -0.82, histogram -0.20 = bearish momentum. Bollinger mid 225.03, price near lower band 181.89 (price 195.84 is inside lower half). 30-day range high 280.80, low 179.53; current is 7.3% above 30d low.
True Sentiment Analysis (Delta 40-60 Options)
From TRUE SENTIMENT OPTIONS (2026-11-20 16:56):
Call Dollar Volume: 9,225,705.00 (55.3%) Put Dollar Volume: 7,458,340.00 (44.7%) Total: 16,684,045.00
Sentiment: Balanced. Call contracts 4,106 vs put 4,092; call trades 80 vs put 59. Pure directional conviction (Delta 40-60) shows slight call tilt but classified Balanced. Near-term expectation: no decisive directional bias. This aligns with technical bearishness but offsets with minor call demand.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.